SENTARA COMMUNITY PLAN
(MEDICAID)

MEDICAL PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: **The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request**. All other information may be filled in by office staff; **fax to 1-844-305-2331**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If information provided is not complete, correct, or legible, authorization can be delayed**.

SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (sJIA) OR ADULT ONSET STILL'S DISEASE (AOSD)

Drug Requested: Ilaris® (canakinumab) **(J0638) (Medical) (Non-Preferred)**

Medication can ONLY be provided by a Physician's office

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ **Date of Birth:** _____

Prescriber Name: _____

Prescriber Signature: _____ **Date:** _____

Office Contact Name: _____

Phone Number: _____ **Fax Number:** _____

DEA OR NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy**: _____

Diagnosis: _____ **ICD Code, if applicable:** _____

Weight: _____ **Date:** _____

☐ Standard Review. In checking this box, the timeframe does not jeopardize the life or health of the member or the member's ability to regain maximum function and would not subject the member to severe pain.

Recommended dosage: every 4 weeks SQ: 4mg/kg (with a maximum of 300mg) > 7.5kg

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

Initial approval - 3 months. For **continued 12-month approval**, please refax form with documentation of CRP or ESR along with progress notes to document therapy effective.

(Continued on next page)

❑ DIAGNOSIS: Systemic Juvenile Idiopathic Arthritis (sJIA)

- ❑ Members must be aged 2 years - 17years

AND

- ❑ Member must have had persistent sJIA activity for a minimum of six (6) months
  - Date of diagnosis must be noted _____

AND

- ❑ Member must have trial and failure of NSAIDs and corticosteroids for > 3 months consecutively within the last 4 months **(paid claims will be reviewed for verification)**

AND

- ❑ Member must have had ≥ 5 active joints with concomitant fever for at least 2 weeks within the last 3 months of this request

OR

- ❑ Member must have had > 2 active joints with concomitant fever for at least 5 days and trial of prednisone or equivalent dosed at 0.5mg/kg/day or 30mg/day within the last 3 months of this request

AND

- ❑ Member must have had CRP (>15 mg/L) within the last 2 months of this year

AND

- ❑ Member must have had ESR (>45mm/hr) within the last 2 months of this year

AND

- ❑ Member must have had fever > 38o C or 100.4o F for at least 2 weeks within the last 2 months of this request

AND

- ❑ Member must have documented failure of Kineret® & either Arcalyst® or Actemra® **(failure is defined as paid claims of Kineret® & Actemra® for at least 6 months AND lab values above did not respond to the preferred drug)**

OR

- ❑ Member has history of anaphylactic reaction to Kineret®, Arcalyst® or Actemra® **[anaphylaxis is defined as an emergency department (ER/ED) visit due to throat or tongue swelling and/or shortness of breath]** or development of skin reactions that lead to Stevens Johnson syndrome.

(Continued on next page)

❑ DIAGNOSIS: Adult Onset Still's Disease (AOSD)

- ❑ Members must be aged ≥ 18 years and ≤ 75 years

AND

- ❑ Member must meet two of the following:
  - ❑ Fever >39 °C, lasting 1 week or longer
  - ❑ Arthralgia or arthritis, lasting 2 weeks or longer
  - ❑ Typical rash
  - ❑ Leukocytosis >10,000/mm3 with >80% polymorphonuclear cells

AND

- ❑ Disease activity based on DAS28 of ≥3.2 at screening

AND

- ❑ Member must have had CRP (>15 mg/L) within the last 2 months of this year

AND

- ❑ Member must have had ESR (>45mm/hr) within the last 2 months of this year

AND

- ❑ At least 4 painful and 4 swollen joints at least 2 weeks within the last 3 months of this request

AND

- ❑ Trial and failure with glucocorticoids, stable dose of ≤10 mg/day (prednisolone or equivalent) for at least 4 weeks AND NSAIDs, at least 4 weeks **(at least 2 weeks within the last 3 months of this request)**

AND

- ❑ Trial and failure Kineret® and either Arcalyst® or Actemra® **(progress notes must be submitted for true failure)**

Reauthorization Approval: 1 year. Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied. Check box below for the Diagnosis that applies.

For sJIA:

- ❑ Documentation decrease ESR <30.mg/L AND ESR<13mm/h

AND

- ❑ Numbered of swollen joints have decreased

(Continued on next page)

For AOSD:

- ❑ Documentation decrease ESR <30.mg/L AND ESR<13mm/h

AND

- ❑ Numbered of swollen joints have decreased

AND

- ❑ DAS28 have decreased <2.6

Progress notes and labs documenting anaphylactic reaction or development of SJS must be submitted.

Medication being provided by a Specialty Pharmacy - PropriumRx

For urgent reviews: Practitioner should call Sentara Health Pre-Authorization Department if they believe a standard review would subject the member to adverse health consequences. Sentara Health's definition of urgent is a lack of treatment that could seriously jeopardize the life or health of the member or the member's ability to regain maximum function.

*****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.*****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****

***Approved by Pharmacy and Therapeutics Committee**: 6/21/2018
REVISED/UPDATED/REFORMATTED: ~~9/29/2018; (Reformatted) 3/16/2019; 7/7/2019; 9/22/2019; 10/7/2019; 11/12/2020;~~ **10/11/2021**;